Literature DB >> 26541438

Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3.

Emanuel Ferreira1, Nuno Oliveira2, Maria Marques2, Luís Francisco3, Ana Santos2, Armando Carreira2, Mário Campos4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26541438     DOI： 10.1016/j.nefro.2015.07.007

Source DB:  PubMed          Journal:  Nefrologia        ISSN： 0211-6995            Impact factor:   2.033


× No keyword cloud information.
  2 in total

1.  Hemolytic uremic syndrome in adults: A case report.

Authors:  Fabiel Gerardo Pérez-Cruz; Patricia Villa-Díaz; María Consuelo Pintado-Delgado; María Loreto Fernández Rodríguez; Ana Blasco-Martínez; María Pérez-Fernández
Journal:  World J Crit Care Med       Date:  2017-05-04

2.  The Relevance of the MCP Risk Polymorphism to the Outcome of aHUS Associated With C3 Mutations. A Case Report.

Authors:  Javier Lumbreras; Marta Subias; Natalia Espinosa; Juana María Ferrer; Emilia Arjona; Santiago Rodríguez de Córdoba
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.